Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Novo Nordisk’ chief executive Lars Fruergaard Jørgensen has agreed to appear at a Senate hearing later this year to defend the pricing of the group’s semaglutide-based therapies for diabetes ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of the active ingredient in those medications have now been linked to at least ...

Both Ozempic and Wegovy are forms of semaglutide, a GLP-1 agonist drug manufactured by Novo Nordisk ... demand for semaglutide within the United States exceeds the available supply.

COPENHAGEN (Reuters) - Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply in that market, its CEO said on Wednesday.

Kennedy has criticized the popular Novo Nordisk NOVOb.CO drug Ozempic, which is often prescribed for weight loss, saying it ...

“For example, your company charges $969 in the United States for one month of Ozempic but just $155 in Canada and just $59 in Germany,” Sanders wrote. While Novo Nordisk pushes for a ban on ...

The Stoxx Europe 600 Index swelled 1.5% to 517.07. Related NewsInflation Rate YoY for Oct in United States is 2.6%, higher ...

(Image Credits: Pixabay) Novo Nordisk said on Monday an oral version ... Novo expects to file for a label expansion for Rybelsus in the United States and the European Union around the turn of ...